Pharmacy Prior Authorization

AETNA BETTER HEALTH ILLINOIS (MEDICAID)

IPF Agents (Medicaid)

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to Aetna Better Health Illinois at 1-855-684-5250.

When conditions are met, we will authorize the coverage of IPF Agents (Medicaid).

Please note that all authorization requests will be reviewed as the AB rated generic (when available) unless states otherwise.

Drug Name (please circle)

Esbriet (pirfenidone)	Ofev (nintedanib)		
Other, please specify			_
Quantity	Frequency Strength		_
Route of Administration			
Patient Information			
Patient Name:			
Patient ID:			
Patient Group No ·			
Patient DOB			
Patient Phone:			
Prescribing Physician			
Physician Name:			
Specialty:	NPI Number:		
Physician Fax:	Physician Phone:		
Physician Address:	City, State, Zip:		
Diagnosis:	ICD Code:		
Please circle the appropriate answ	er for each question.		
 Has this plan authorized previous authorization is 	this medication in the past for this patient (i.e., on file under this plan)?	Y	N
[If no, skip to question 6.]		
2. Has the patient's forced starting the medication?	vital capacity (FVC) stabilized or improved since	Y	Ν
*Note: Discontinuation o 10% decline in FVC ove	f therapy is recommended if there is a greater than r a 12 month period.		
[If no, then no further qu	estions.]		

3.	Are liver function tests (LFTs) being monitored?	Y	Ν
	[If no, then no further questions.]		
4.	Is the patient compliant with treatment?	Y	Ν
	[If no, then no further questions.]		
5.	Is the patient a current smoker?	Y	Ν
	[No further questions.]		
6.	Does the patient have a diagnosis of idiopathic pulmonary fibrosis which has been confirmed by high resolution computed tomography (HRCT) demonstrating usual interstitial pneumonia (UIP) or surgical lung biopsy demonstrating UIP?	Y	Ν
	[If no, then no further questions.]		
7.	Does the patient have a baseline forced vital capacity (FVC) of at least 50% predicted?	Y	Ν
	[If no, then no further questions.]		
8.	Does the patient have a baseline carbon monoxide diffusion capacity (DLco) of at least 30%?	Y	Ν
	[If no, then no further questions.]		
9.	Is there documentation of baseline liver function tests (LFTs) prior to initiating treatment?	Y	Ν
	[If no, then no further questions.]		
10	. Is the patient at least 18 years of age?	Y	Ν
	[If no, then no further questions.]		
11	. Is the patient a current smoker?	Y	Ν
	[If yes, then no further questions.]		
12	. Is therapy being prescribed by, or in consultation with, a pulmonologist?	Y	Ν
Con	nments:		

I affirm that the information given on this form is true and accurate as of this date.

Prescriber (Or Authorized) Signature	Date	
Reference Number: C7837-A / Effective Date: 12/01/2017		